792 / 1266
Conclusions
Need to develop and validate new response criteria e.g.
RANO & RAPNO
Must consider drug delivery as a vital component of neuro-
oncology trials & possible reason for an active agent
failing!
Efficient, adaptive and flexible clinical trial designs
allow study of multiple arms
combination targeted therapies
parallel and sequentially